Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Platinum was the first drug with proven activity against gastric cancer (GC), the combination with fluoropyrimidine is the standard first-line systemic therapy for patients of GC. However, a major cause of treatment failure still is the existence of drug resistance. The purpose of this study is to identify and validate the platinum-related genes in GC and to construct a multi-gene joint signature for predicting the prognosis of GC patients.
Methods: Based on 326 platinum-related genes from GeneCards, GO and KEGG analysis were applied for differentially expressed genes in GC, UniCox regression analysis was used to select effective genes and Lasso-Cox regression was utilized to construct a prognosis model. Stratified analysis, CNV landscape, TMB and MSI status, HLA gene expression, GSEA and GSVA analysis, immune activities, immunotherapy sensitivities were evaluated in the resistant high and low groups. Drug resistant cell lines, PDO and PDX models were used to validate this signature.
Results: GO analysis of 140 differentially expressed genes were involved in many processes and KEGG pathways were enriched in platinum resistance and cancer. UniCox regression analysis was screened out 21 genes and conducted a platinum resistance scoring model. Stratified analysis indicated that the drug resistance score had a good predictive value in subgroups divided by T-stage, age and race. CNV changes were more occurred in the score-high group, and most model genes were negatively correlated with TMB, MSI and HLA gene expression. The immune score in resistant group was significantly higher, within more mast cell, regulatory T cell and dendritic cell infiltrated in. In vitro and in vivo models showed that 21 platinum resistance genes had varying degrees of upregulation under CDDP chemotherapy pressure.
Conclusions: The 21 gene-signature for platinum was developed to predict response to platinum chemotherapy for GC patients. It is worthwhile to further evaluate the molecular biology and the clinical applications of this signature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995506 | PMC |
| http://dx.doi.org/10.1186/s12935-025-03777-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Size-Controlled and Sintering-Resistant Sub-3 nm Pt Nanoparticles on Graphene by Temperature-Variation Atomic Layer Deposition.
Langmuir
September 2025
Product & Process Engineering, Department of Chemical Engineering, Faculty of Applied Sciences, Delft University of Technology, 2629 HZ Delft, The Netherlands.
Noble metal nanoparticles (NPs), particularly platinum (Pt), are widely used in heterogeneous catalysis due to their exceptional activity. However, controlling their size and preventing sintering during synthesis remains a major challenge, especially when aiming for high dispersion and stability on supports such as graphene. Atomic layer deposition (ALD) has emerged as a promising method to address these issues, yet conventional processes often lead to broad particle size distributions (PSDs).
View Article and Find Full Text PDFSebaceous Carcinoma of the Breast: A Case Report and Review of the Literature.
Cureus
August 2025
Medical Oncology, Mohammed VI University Hospital of Marrakech, Marrakesh, MAR.
Sebaceous carcinoma of the breast is a rare and poorly understood variant of metaplastic breast carcinoma. Its histogenesis, clinical behavior, and optimal management remain unclear due to the limited number of reported cases. We report the case of a 78-year-old woman presenting with a six-month history of a right axillary mass and inflammatory changes in the right breast.
View Article and Find Full Text PDFABL1-mediated tyrosine phosphorylation of SYCP2 contributes to transcription-coupled homologous recombination and platinum resistance in ovarian cancer.
NAR Cancer
September 2025
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, 213 Research Drive, Durham, NC 27710, United States.
Treatment of patients with platinum-resistant ovarian cancer is a major clinical challenge. We found that high expression of a meiotic protein, Synaptonemal Complex Protein 2 (SYCP2), is associated with platinum resistance and tyrosine kinase ABL1 inhibitor sensitivity in ovarian cancer. We demonstrate that tyrosine kinase ABL1 inhibitors inhibit cancer cell proliferation more efficiently in ovarian cancer cell lines with SYCP2 overexpression.
View Article and Find Full Text PDFMevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.
Protein Pept Lett
September 2025
Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu, China.
Introduction: Dysregulation of mevalonate metabolism is a hallmark of tumorigenesis and therapy resistance across malignancies, though its role in bladder cancer remains unclear. This study aimed to elucidate its impact on prognosis and cisplatin chemosensitivity in bladder cancer.
Methods: Transcriptomic data and clinical information of bladder cancer patients were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases.
Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.
Int J Gynecol Cancer
July 2025
University of California, Los Angeles, Department of Gynecologic Oncology, Los Angeles, CA, USA.
Objective: To evaluate prescribing patterns, toxicities, and outcomes among patients receiving mirvetuximab for platinum-resistant ovarian cancer.
Methods: This retrospective study included patients with platinum-resistant ovarian cancer with high folate receptor alpha expression treated with mirvetuximab at a single institution (2018-2023). Patients were categorized based on treatment immediately preceding mirvetuximab: the taxane group received taxane treatment; the non-taxane group received other therapy.